Shots:
The US FDA has received NDA for Immunome’svaregacestat for the treatment of adults with desmoid tumors
NDA is supported by the global P-III (RINGSIDE) trial assessing varegacestat (1.2mg, QD) vs PBO until disease progression or death in 156 pts with progressing desmoid tumors; eligible pts could then enter OLE phase, which is ongoing
Trial…
